ClinicalTrials.gg
Not yet recruitingNCT05766215Updated Sep 28, 2023

Nurse-led Therapeutic Education Effects in Glycemic Control and Knowledge of Type 1 Diabetes Mellitus Patients Under Hospital Transition

An interventional study of Therapeutic Education in Nurse's Role, sponsored by Hospitales Universitarios Virgen del Rocío. Not yet recruiting at 1 site in Spain. Open to participants aged 17 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-28.

Sponsored by Hospitales Universitarios Virgen del Rocío · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Jan 2024, 2 years 9 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
17 Years to 18 Years
Sex
All
01

Study summary

The goal of this interventional quasiexperimental study is to learn about the influence of therapeutic education carried out by nurses in the management and knowledge of patients with T1DM. Participants will be:

Given several therapeutic education sessions. Evaluated using different questionnaires and anthropometric measures.

Read the detailed description

The main objective of the study will be to determine the influence of therapeutic education carried out by nurses in the management and knowledge of patients with T1DM who will make a hospital transition. The research design will be a single-blind, nonrandomized, quasi-experimental, single-center, 1-group controlled study .

It will be developed at the Center for Diagnosis and Treatment (CDT) of the Virgen del Rocío University Hospital (HUVR), in Seville (Spain). The participant selection process will be carried out considering that only 13 adolescents 17 and 18 years and younger with T1DM, belonging to the reference hospital area, will transit from the Children's Hospital to the Adult Hospital. It is estimated that the study will have a sample of a minimum of n=10, which will be studied over 12 months.

Given the existing bibliography about the benefits of this intervention , 1 it is expected that the glycosylated hemoglobin (HbA1c) of patients will be less than 7%, which together with the Self-Management Adherence Questionnaire for Diabetes Treatment (SCI-R. es) 2 represents that patients perform adequate management of their disease. The Survey of Eating Problems in Diabetes Summary Questionnaire (EPAD-R) 3 will be used to assess their eating behavior. An improvement in people's knowledge regarding hypoglycemia is also sought, measured with the Clarke test 4 ; and an improvement in the quality of life, measured with the SF-12 questionnaire 5 and family support with the Apgar test 6 .

The therapeutic plan consists of preparing the process prior to discharge from the pediatric center, transferring to the adult hospital with a clinical and educational report and a previously arranged visit to the new unit. The heads of both teams coordinate the structure and the transition process with regular meetings. From the Adult Diabetes Day Hospital, a joint visit is reserved with the endocrinologist and the nurse educator. They are integrated into a 12-month therapeutic care and education program. It consists of four structured phases: 1. Welcome nurse visit, 2. Diabetologic education course adapted to the detected needs, 3. Individualized follow-up through alternating quarterly appointments between nurses and endocrine physician, 4. Evaluation and discharge of the program.

At the beginning (baseline visit), at 3 and 12 months the following variables are recorded:

  1. Age (years), sex (female/male), T1DM evolution (years).
  2. Treatment type (basal-bolus/insulin pump). Sensor usage time (>80%)
  3. Metabolic control: HbA1C (mg/ dL ), Time in Range (TIR), Time Above Range (TAR), Time Below Range (TBR), Coefficient of Variation (CV), Mean Glucose (GMI), weight (Kg), height (cm), BMI (Kg/m 2 ).
  4. Perception of quality of life. Test SF-12, of 12 questions.
  5. Perception of symptoms of hypoglycemia. Clarke test, 8 questions.
  6. Eating behavior, with the EPAD-R test, of 16 questions.
  7. Adherence to diabetes treatment. SCI-R.es test. The results analysis plan will be carried out using Microsoft Excel, SPSS or R Commander computer programs , in which the relationships between the descriptive statistics extracted from the screened data will be explored to prevent duplicates. The same digital tools will be used to guarantee the protection of the data and variables collected. This aspect is detailed in the attached informed consent.

Regarding the ethical and legal aspects of the study, it is worth mentioning the benefit in disease management, quality of life and general satisfaction that the protocolized follow-up will cause in adolescents. No risk to the psychosocial integrity of the population involved in the study has been detected.

The necessary facilities will be the Education Classroom of the HUVR Diabetes Day Hospital, computer support through 2 computers, paper resources for the questionnaires, 2 nurses and 1 endocrinologist will be necessary as human resources. The authors declare the absence of funding or conflict of interest for the development of the research.

02

Conditions studied

  • Nurse's Role

Keywords

  • type 1 diabetes mellitus
  • health education
  • glycated hemoglobin A
  • health-related knowledge
03

In context

Diabetes Mellitus, Type 1

3,754 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

This study's planned enrollment of 13 is below the median of 40 across 2,820 interventional studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

Hospitales Universitarios Virgen del Rocío is the lead sponsor of 33 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
17 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 17 years.

Exclusion criteria

Exclusion Criteria:

  • Unable to give .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (estimated)

Study arms

  • Experimental
    Therapeutic patients education

    3 sessions of structured therapeutic patient education (TPE) in which diet, exercise, alcohol abuse and insulin or pharmacological treatment management advise is given.

    Behavioral: Therapeutic Education

Interventions

  • BehavioralTherapeutic Education

    It consists of four structured phases: 1. Welcome nurse visit, 2. Diabetologic education course adapted to the detected needs, 3. Individualized follow-up through alternating quarterly appointments between nurses and endocrine physician, 4. Evaluation and discharge of the program

06

What researchers measure

Primary outcomes

  1. Glycated hemoglobin.

    HbA1c

    Time frame: 12 months

  2. Time in Range

    TIR

    Time frame: 12 months

  3. Time above range

    TAR

    Time frame: 12 months

  4. Time below range

    TBR

    Time frame: 12 months

  5. Coefficient of variation

    CV

    Time frame: 12 months

  6. Glucose Management Indicator

    GMI

    Time frame: 12 months

  7. Weight

    Kg

    Time frame: 12 months

  8. Height

    cm

    Time frame: 12 months

  9. Body Mass Index

    BMI

    Time frame: 12 months

Secondary outcomes

  1. Perception of quality of life.

    SF-12

    Time frame: 12 months

  2. Perception of symptoms of hypoglycemia

    Clarke

    Time frame: 12 months

  3. Eating behavior,

    EPAD-R

    Time frame: 12 months

  4. Adherence to diabetes treatment

    SCI-R

    Time frame: 12 months

Other outcomes

  1. Treatment type

    basal-bonus, insulin pump, sensor usage range

    Time frame: 12 months

  2. Demographical information

    Age (years), sex (female/male), T1DM evolution (years).

    Time frame: 12 months

07

Study locations

1 site
  • Hospitales Universitarios Virgen del Rocío
    Sevilla, 41013, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2023; primary completion for Jan 2024, 3 months later.

Of 844 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 38. This study's planned 3 months is below that.

Counting every sponsor, half of 949 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2022
First posted
Mar 13, 2023
StartEst.
Sep 30, 2023
Primary completionEst.
Jan 22, 2024
CompletionEst.
Dec 22, 2024
Last update
Sep 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05766215
Lead sponsor
Hospitales Universitarios Virgen del Rocío
Responsible party
Pilar Santa Cruz Álvarez (Enfermera de Práctica Avanzada (EPA), Hospitales Universitarios Virgen del Rocío) — Principal investigator
First posted
Mar 13, 2023
Start date
Sep 30, 2023 (estimated)
Primary completion
Jan 22, 2024 (estimated)
Completion
Dec 22, 2024 (estimated)
Last update
Sep 28, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion